Advanced Proteome Therapeutics (STU:0E81) Other Stockholders Equity: €-0.00 Mil (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Other Stockholders Equity?

Advanced Proteome Therapeutics STU:0E81 Other Stockholders Equity is €-0.00 Mil as of Apr. 2023.

Advanced Proteome Therapeutics's Other Stockholders Equity for the quarter that ended in Apr. 2023 was €-0.00 Mil.

Advanced Proteome Therapeutics's quarterly Other Stockholders Equity declined from Oct. 2022 (€0.00 Mil) to Jan. 2023 (€-0.00 Mil) but then increased from Jan. 2023 (€-0.00 Mil) to Apr. 2023 (€-0.00 Mil).

Advanced Proteome Therapeutics's annual Other Stockholders Equity increased from Jul. 2020 (€-0.00 Mil) to Jul. 2021 (€0.00 Mil) and increased from Jul. 2021 (€0.00 Mil) to Jul. 2022 (€0.27 Mil).

Advanced Proteome Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Other Stockholders Equity Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.27

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.27 0.00 -0.00 -0.00

Advanced Proteome Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a Other Stockholders Equity of €-0.00 Mil as of Apr. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Other Stockholders Equity too high?
Advanced Proteome Therapeutics' current Other Stockholders Equity is €-0.00 Mil.
How does Advanced Proteome Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
Advanced Proteome Therapeutics' Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Other Stockholders Equity of €-0.00 Mil. The current Other Stockholders Equity is €-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Other Stockholders Equity is €-0.00 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.